Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing
Executive Summary
Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8
You may also be interested in...
Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns
The Medicare prescription drug benefit will be implemented by a new team at the Centers for Medicare & Medicaid Services following the Dec. 16 departure of CMS Administrator Tom Scully
Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns
The Medicare prescription drug benefit will be implemented by a new team at the Centers for Medicare & Medicaid Services following the Dec. 16 departure of CMS Administrator Tom Scully
Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman
Medicare drug benefit legislation will ultimately cost well over the $400 bil. budget target, Rep. Henry Waxman (D-Calif.) predicted Oct. 29